

Contents

Preface

V

1 Introduction 1

Jürgen Borlak

- 1.1 A Shift in Paradigm 1
- 1.2 Enabling Technologies Lead to New Founded Knowledge in Genomic Science 3
- 1.3 Translating RNAs Into Proteins 4
- 1.4 Toxicogenomics – A Perspective 5

Technology Platforms in Toxicogenomics

2 Expression Profiling using SAGE and cDNA Arrays 9

Andreas Bosio

- 2.1 Introduction 9
- 2.2 SAGE Technology 10
- 2.2.1 Principles of SAGE Technology 10
- 2.2.2 Generation of SAGE Libraries 11
- 2.2.3 SAGE Bioinformatics 12
- 2.2.4 SAGE Applications 13
- 2.3 cDNA Arrays 14
- 2.3.1 Principles of PIQOR Technology 14
- 2.3.2 Selection and Annotation of Suitable cDNA Fragments 16
- 2.3.3 Production of Microarrays 17
- 2.3.4 Application of Microarrays 19
- 2.3.5 Array Data: Acquisition, Analysis, and Mining 20
- 2.4 Integrated Approaches using Microarrays 23
- 2.5 Combination of Microarrays and SAGE 24
- References 25

3	Oligo Arrays, Global Transcriptome Analysis	27
	<i>Jacques Retief, Earl Hubbell, and David Finkelstein</i>	
3.1	Introduction to GeneChip® Microarray Technology	27
3.1.1	Introduction to RNA Expression Microarrays	27
3.1.2	GeneChip® RNA Expression Microarray Technology	27
3.1.3	Biological Annotations	35
3.1.4	Conclusions	43
3.1.5	Introduction to GeneChip® DNA mapping microarrays	44
3.1.6	GeneChip® DNA Mapping Microarray Technology	45
3.1.7	Conclusion	47
3.2	Experimental Design and Data Analysis	47
3.2.1	Introduction	47
3.2.2	Experimental Design	48
3.2.3	Data Assessment and Correction	66
3.2.4	Comparing Results	71
3.2.5	Conclusions	77
	<i>References</i>	78
4	Toxicogenomics Applications of Open-platform High Density DNA Microarrays	83
	<i>Mark McCormick and Emile F. Nuwaysir</i>	
4.1	Introduction	83
4.2	Genome-scale Expression Profiling	87
4.3	Multiplex Array Hybridization with NimbleScreen 12	88
4.4	NimbleScreen 4	90
4.5	Software for Open-platform Array Design	92
4.6	Multiplex Array Control Elements	93
4.7	Multiplex Array Consistency	93
4.8	Conclusions	94
	<i>References</i>	99
5	Mass Spectrometry and Proteomics: Principles and Applications	97
	<i>Uwe Rapp</i>	
5.1	Introduction	97
5.2	Analysis Tools in Proteomics	98
5.2.1	Separation Techniques	98
5.2.2	Mass Spectrometric Techniques	99
5.3	Application	100
5.3.1	Experimental Details	100
5.3.2	Results	101
5.3.3	Top-Down Analysis	112
5.4	Summary and Outlook	112
	<i>References</i>	113

6	Covalent Protein Modification Analysis by Electrospray Tandem Mass Spectrometry	115
	<i>Wolf D. Lehmann</i>	
6.1	Introduction	115
6.2	Electrospray Ionization	117
6.3	Tandem Mass Spectrometry	117
6.4	Q-TOF and Q-FT-ICR Systems	119
6.4.1	Resolution	119
6.4.2	Mass Accuracy	120
6.5	Peptide Sequencing by Electrospray Tandem Mass Spectrometry	121
6.6	Protein Modifications and their MS/MS Reactions	122
6.7	Detection of Protein Modifications by MS and MS/MS	124
6.7.1	Phosphorylation	126
6.7.2	Tyrosine Sulfation	132
6.7.3	Redox-related Modifications	132
6.7.4	Myristylation	132
6.7.5	Acetylation	133
6.7.6	Methylation	135
6.7.7	Glycosylation	135
6.7.8	Ubiquitination	135
6.7.9	Isoaspartate Formation	136
6.8	Summary and Outlook	136
	<i>References</i>	137
7	Chromatin Immunoprecipitation-based Identification of Gene Regulatory Networks	143
	<i>Monika Niehof and Jürgen Borlak</i>	
7.1	Introduction	143
7.1.1	Importance of Identifying Transcriptional Regulatory Networks in Toxicogenomics	143
7.1.2	Chromatin Immunoprecipitation to Analyze Target Genes	144
7.2	Description of Methods	144
7.2.1	Crosslinking Applications	144
7.2.2	Chromatin Fragmentation	146
7.2.3	Immunoprecipitation of Proteins	147
7.2.4	DNA Isolation and PCR Analyses	148
7.2.5	Cloning Strategies	148
7.2.6	Target Validation	150
7.3	Successfully Reported ChIP Cloning for New Target Identification	151
7.4	Problems and Potential Strategies	153
7.4.1	Elimination of Nonspecific DNA and Protein–Protein Crosslinking	153
7.4.2	Enrichment of Target Promoters and High-throughput Screening	153
7.5	Challenges for the Future	155
	<i>References</i>	157

8	NMR Spectroscopy as a Versatile Analytical Platform for Toxicology Research	163
	<i>Olivia Corcoran</i>	
8.1	A Role for NMR in Toxicogenomics	163
8.2	Evolution of NMR Technologies in Toxicology Research	164
8.2.1	Conventional NMR Spectroscopy	165
8.2.2	Flow NMR Methods	168
8.2.3	HRMAS NMR of Tissues	170
8.3	Metabolite Profiling by NMR	170
8.3.1	Inborn Errors of Metabolism	171
8.3.2	Reactive Metabolites	172
8.3.3	Animal Models of Toxicity	173
8.4	Biomarkers of Toxicity	173
8.4.1	Organ Toxicity	174
8.4.2	Forensic and Chemical Warfare Toxicology	175
8.4.3	Environmental Toxicity	176
8.5	Improvements in NMR Technology	177
8.5.1	Sensitivity and Throughput	177
8.5.2	Integrated NMR Chemical Analyzer	178
8.5.3	Metabolic and Genetic Profiling	179
8.6	Conclusions	179
	<i>References</i>	180

Bioinformatic Tools in Toxicogenomics

9	Generation and Validation of a Reference System for Toxicogenomics DNA Microarray Experiments	187
	<i>Jürgen Cox, Hans Gmündner, Andreas Hohn, and Hubert Rehrauer</i>	
9.1	Genomics and DNA Microarrays	187
9.2	Toxicogenomics	188
9.2.1	Challenges of Conventional Toxicology Approaches	188
9.2.2	Opportunities for Genomics	188
9.3	Processes and Methods for Toxicogenomics	188
9.3.1	Experimental Design	188
9.3.2	Data Quality Assessment	189
9.3.3	Reference Compendium Generation	190
9.3.4	Classification	191
9.4	Diagnosis of Microarray Data Quality	191
9.4.1	Sample Preparation	191
9.4.2	Dye Incorporation	192
9.4.3	Distortion	192
9.4.4	Impurities	193
9.4.5	Scanner Settings	193

9.4.6	Automation of Data Quality Control	193
9.4.7	Preprocessing of Microarray Data	193
9.5	Generating a Reference Compendium of Compounds	194
9.5.1	Cross Validation	195
9.6	Mechanism of Action	198
9.6.1	Alternative Structuring of Profiling Data	198
9.6.2	Promoter Analysis	199
9.6.3	Pathways	199
9.6.4	Mapping Gene Expression Profiles onto Genomes	199
9.6.5	<i>In silico</i> Comparative Genomics	199
9.7	Outlook	200
	References	200
10	The Chemical Effects in Biological Systems (CEBS) Knowledge Base	201
	<i>Michael D. Waters, Gary Boorman, Pierre Bushel, Michael Cunningham, Rick Irwin, Alex Merrick, Kenneth Olden, Richard Paules, James K. Selkirk, Stanley Stasiewicz, Ben Van Houten, Nigel Walker, Brenda Weis, Honghui Wan, and Raymond Tennant</i>	
10.1	Overview	201
10.2	NCT Intramural Research	204
10.3	Toxicogenomics Research Partnerships	206
10.4	Microarray Analysis	207
10.5	Implementation of a CEBS Prototype	208
10.6	Systems Toxicology: Bioinformatics and Interpretive Challenges	210
10.7	Understanding Functions of Biomarkers	211
10.7.1	Microarray Expression Profile Analysis	211
10.7.2	Coevolutional Profile Analysis	212
10.7.3	Domain Fusion Analysis	213
10.7.4	Structural Analysis	213
10.7.5	Text Mining in MEDLINE Based on Literature Profile Comparison	213
10.7.6	Integrative Analysis	214
10.8	Phased Development of the CEBS Knowledge Base	214
10.8.1	CEBS Phase I: Microarray/Gene Expression Data, Toxicology/Pathology Data and Associated Analysis Tools	214
10.8.2	CEBS Phase II: Protein Expression Database and Metabolomics Datasets	219
10.8.3	CEBS Phase III: Integrate Microarray/Gene Expression and Protein Expression Databases using a Gene/Protein Group Strategy	220
10.8.4	CEBS Phase IV: Knowledge Technology	221
10.9	Conclusions	226
	References	229

11	Investigating the Effective Range of Agents by Using Integrative Modelling	233
	<i>Andreas Freier, Ralf Hofestädt, and Thoralf Toepel</i>	
11.1	Introduction	233
11.2	Mathematical Models	235
11.3	Modelling Molecular Databases	237
11.3.1	Drug Databases	237
11.3.2	Pathway Databases	238
11.3.3	Gene Expression Databases and Others	239
11.4	Integrative Modelling	240
11.4.1	Data Preprocessing	241
11.4.2	Object Oriented Models and Data Integration	241
11.4.2	Process Oriented Modelling Using Views	244
11.4.3	System Oriented Modelling and Simulation	246
11.4.4	Implementation	248
11.5	Summary	249
	<i>References</i>	250
12	Databases and Tools for <i>in silico</i> Analysis of Regulation of Gene Expression	253
	<i>Alexander Kel, Olga Kel-Margoulis, and Edgar Wingender</i>	
12.1	Introduction	253
12.2	Concepts of Gene Regulation	253
12.2.1	Transcription Factors	254
12.2.2	Modern Concepts of the Structure and Function of the Gene-regulation Regions in the Genome	255
12.3	Databases Relating to Gene Regulation	260
12.3.1	TRANSFAC Database	262
12.4	Regulatory Sequence-analysis Tools and Approaches	263
12.4.1	Motif Analysis	264
12.4.2	Recognition of TF Binding Sites	266
12.4.3	Recognition of Composite Regulatory Elements	272
12.4.4	Analysis of Promoters	275
12.4.5	Functional Classification of Promoters and Prediction of Gene Regulation	279
12.4.6	Phylogenetic Footprinting	281
12.5	Analysis of Gene Expression Data	281
12.5.1	Analysis of the Promoters of Coregulated Genes	282
	<i>References</i>	285

13	Systems Biology Applied to Toxicogenomics	291
	<i>Klaus Prank, Matthias Höchsmann, Björn Oleson, Thomas Schmidt, Leila Taher, and Dion Whitehead</i>	
13.1	Introduction to Systems Biology	291
13.1.1	System-level Understanding of Biological Systems	294
13.1.2	Measurement Technology and Experimental Approaches	301
13.2	Data Mining and Reverse Engineering of Regulatory Networks	305
13.2.1	Data Mining Techniques	305
13.2.2	Inferring Gene Regulatory Networks from Gene Expression Data	307
13.2.3	Reverse Engineering of Metabolic and Signal-transduction Pathways	308
13.3	Modelling and Simulation Software	310
13.3.1	Automated Model Generation	310
13.3.2	Parser	311
13.3.3	Systems Biology Workbench and Markup Languages	313
13.3.4	Parameter Estimation	317
13.3.5	Simulators	318
13.3.6	Visualization	320
13.4	Toward Predictive <i>in silico</i> Toxicogenomics	320
13.4.1	A Systems Biology Approach to <i>ab initio</i> Hepatotoxicity Testing	320
13.4.2	<i>In silico</i> Toxicogenomics for Personalized Medicine	321
13.4.3	Future of Predictive <i>in silico</i> Toxicity Testing in the R&D Process	321
	<i>References</i>	322

Application of Toxicogenomic: Case Studies

14	Regulatory Networks of Liver-enriched Transcription Factors in Liver Biology and Disease	327
	<i>Jürgen Borlak, Jürgen Klempnauer, and Harald Schrem</i>	
14.1	Introduction	327
14.2	The HNF-1/HNF-4 Network for Liver-specific Gene Expression	328
14.2.1	HNF-1 Regulates HNF-4alpha Expression	329
14.2.2	HNF-1alpha and HNF-4 Regulate HNF-1alpha Expression	329
14.2.3	Dimerization Cofactor of HNF-1alpha and Liver-specific Gene Expression	331
14.2.4	Agonistic and Antagonistic Ligands for the Orphan Nuclear Receptor HNF-4alpha	331
14.2.5	Coactivators for HNF-1 and HNF-4 and Their Network Effects in Liver Biology	334
14.2.6	The Relevance of HNF-4alpha Splice Variants in Differential Transcriptional Regulation	336
14.2.7	Activation and Repression by Homo- and Heterodimerization of HNF-4alpha Proteins	336

14.2.8	Posttranscriptional Modification of HNF-4 Function by Phosphorylation and Acetylation	337
14.2.9	Cooperation and Competition between COUP-TF and HNF-4	337
14.2.10	The Role of HNFs in CYP Monooxygenase Expression	338
14.3	HNF-6 and HNF-3beta in Liver-specific Transcription Factor Networks	339
14.3.1	HNF-6, OC-2, HNF-3beta, and C/EBPs Regulate HNF-3beta Expression	339
14.3.2	Competition and Cooperation between HNF-3alpha and HNF-3beta	340
14.4	The Role of C/EBPs in Diverse Physiological Functions	340
14.4.1	C/EBP-alpha in Energy Metabolism and Detoxification	340
14.4.2	C/EBP-beta in Energy Metabolism	343
14.4.3	C/EBPs in the Acute-phase Response	344
14.4.4	Protein–Protein Interactions of C/EBP-beta during the Acute-phase Response	347
14.4.5	C/EBPs in Liver Regeneration	348
14.4.6	C/EBPs and Apoptosis	349
14.4.7	C/EBPs in Liver Development	350
14.4.8	The Role of C/EBPs in CYP Monooxygenase Expression during Development	350
14.4.9	C/EBPs and Their Role in Liver Tumour Biology	351
14.5	Involvement of C/EBP-alpha and C/EBP-beta in Regulation of Cell Cycle Control	352
14.5.1	C/EBP-alpha Expression and Growth Arrest	352
14.5.2	Glucocorticoid-induced G1 Cell Cycle Arrest Is Mediated by C/EBP-alpha	352
14.5.3	Protein–Protein Interactions between p21, cdk2, cdk4, and C/EBP-alpha	354
14.5.4	C/EBP-alpha and p107 Protein–Protein Interaction Disrupts E2F Complexes	355
14.5.5	C/EBP-beta Arrests the Cell Cycle before the G1/S Boundary	356
14.6	DBP Circadian Gene Regulation in the Liver	356
14.7	Conclusions and Outlook	358
	References	360
15	Toxicogenomics Applied to Understanding Cholestasis and Steatosis in the Liver	369
	<i>Timothy W. Gant, Peter Greaves, Andrew G. Smith, and Andreas Gescher</i>	
15.1	Introduction	369
15.2	Models of Cholestasis and Steatosis	370
15.2.1	The <i>Fech</i> Mouse	370
15.2.2	Griseofulvin	371
15.2.3	ET743	371
15.2.4	Alpha-naphthylisothiocyanate (ANIT)	371

15.3	Pathological and Biochemical Characterization of the Models	372
15.3.1	Pathological Characterization	372
15.3.2	Protoporphyrin IX levels in Models of Ferrochelatase Inhibition	374
15.4	Microarray and Bioinformatics Methodology	375
15.5	Liver Gene Expression Altered Directly as a Response to Griseofulvin	377
15.5.1	Genes of the Heme Synthesis and Catabolism Pathways	377
15.5.2	Monoxygenases	380
15.6	Gene Expression Changes Associated with Pathological Changes	381
15.6.1	Gene Expression Associated with Inflammation	381
15.6.2	CD24a	383
15.6.3	Annexins and Liver Damage or Maybe Cholestasis?	383
15.6.4	Fibrosis and Mallory Body Formation	383
15.7	Gleaning New Information on Pathological Changes from Gene Expression Data	387
15.8	Conclusions	389
	References	392

16 Toxicogenomics Applied to Cardiovascular Toxicity 395

Thomas Thum and Jürgen Borlak

16.1	Introduction	395
16.2	Toxicogenomics Applied to Cardiovascular Toxicity	395
16.2.1	Drug-induced Cardiac Arrhythmias	395
16.2.2	Drug-induced Myocardial Apoptosis and Necrosis	396
16.2.3	Drug-induced Cardiomyopathy and Myocardial Remodelling	398
16.2.4	Drug-induced Myocarditis and Inflammation	399
16.2.5	Drug-induced Effects on Cardiac Contractility	399
16.2.6	Drug-induced Cardiac Hypertrophy	399
16.2.7	Drug-induced Vascular Injury	400
16.3	Environmental Pollution and Cardiotoxicity: Effect of Halogenated Aromatic Hydrocarbons	401
16.4	Importance of Single Nucleotide Polymorphisms (SNPs) and Tissue-specific Drug Metabolism in Cardiovascular Drug Therapy	402
16.4.1	Single Nucleotide Polymorphisms and Drug Treatment of Cardiovascular Diseases	402
16.4.2	Tissue-specific Metabolism in Cardiovascular Tissues	405
16.5	Conclusions	405
	References	406

17 Toxicogenomics Applied to Endocrine Disruption 413

Damian G. Deavall, Jonathan G. Moggs, and George Orphanides

17.1	Introduction	413
17.1.1	Introduction to Endocrine Disruption	413
17.1.2	Therapeutic Endocrine Modulators	415

17.2	Molecular Mechanisms of Estrogen Signalling	416
17.2.1	Introduction to Estrogen Receptor Action	417
17.2.2	Extranuclear Action of Estrogen Receptors Signalling Through Kinase Cascades to Pleiotropic Transcriptional Effects	417
17.3	Current Methods for Assessing Endocrine-disrupting Potential	418
17.3.1	Nuclear Receptor Binding Assays and Yeast Transactivation Assays	418
17.3.2	End-point In-vivo Assays for Potential Endocrine Disruptors	419
17.4	Value of Toxicogenomic Platforms to ED Toxicology	420
17.4.1	Genome-scale Microarray Experiments Facilitate a Global View of Gene Expression	420
17.4.2	Experimental Design	424
17.5	Data Interpretation	425
17.5.1	The Use of Hierarchical Gene Clustering to Fingerprint ED Modes of Action Will Allow Mechanistic Determination	425
17.5.2	Pathway Analysis of ED Action	426
17.5.3	Predictive Testing of ED Potential Based on Transcript Profiling	428
17.6	Summary	429
	References	430
18	Toxicogenomics Applied to Teratogenicity Studies	435
	<i>Philip G. Hewitt, Peter-J. Kramer, and Jürgen Borlak</i>	
18.1	Introduction	435
18.1.1	Current Testing Strategies: Established Procedures	438
18.1.2	Calcium Signalling and Foetal Development	439
18.1.3	Effect of Dose on Embryo Development	440
18.1.4	Effect of Time on Embryo Development	441
18.1.5	Issues Linked to the Placenta as a Barrier	441
18.1.6	Effect of Xenobiotic and Endogenous Metabolism	442
18.1.7	Mechanisms of Teratogenicity	443
18.2	Alternative Methods	443
18.2.1	Embryonic Stem Cells	443
18.2.2	Micromasses and Other Cell Culture Systems	444
18.2.3	Whole-embryo Culture	444
18.2.4	Gene Expression Profiling	445
18.2.5	In Silico Studies	445
18.3	Molecular Aspects of Teratogenicity	445
18.3.1	Genes Responsible for Causing Birth Defects	445
18.3.2	Specific Genes Involved in Birth Defects	447
18.4	Case Study: Elucidation of Mechanisms of Teratogenic Toxicity of the Developmental Drug EMD 82571	448
18.4.1	Properties of EMD 57033 and EMD 82571	448
18.4.2	Hypothesis-driven Gene Expression Array	450
18.4.3	Global Expression Array (Affymetrix)	453
18.4.4	Results and Discussion	454

18.5	Importance of Surrogate Markers for Prediction of Teratogenicity	464
18.6	Summary and Future of Gene Expression Profiling for Teratogenicity Studies	464
	References	465
19	Toxicogenomics Applied to Nephrotoxicity	471
	<i>Anke Lühe and Heinz Hildebrand</i>	
19.1	Brief Survey of Nephrotoxicity	471
19.1.1	Relevance and Occurrence of Nephrotoxic Effects	471
19.1.2	Different Modes of Nephrotoxicity	472
19.1.3	Actual Situation in Diagnosis and Mechanistic Investigation	474
19.1.4	New Perspectives Offered by Toxicogenomics	475
19.2	Toxicogenomic Approaches in Prediction of Toxicity and Mechanistic Studies (Case Studies)	476
19.2.1	Prediction of Toxicity: Toxicogenomics Aimed at the Identification of Markers of Renal Toxicity ('Fingerprinting')	476
19.2.2	Mechanistic Studies: Toxicogenomics Aimed at Elucidating the Mode of Nephrotoxic Action	478
19.3	Perspectives	483
	References	484
20	Toxicogenomic Analysis of Human Umbilical Cords to Establish a New Risk Assessment of Human Foetal Exposure to Multiple Chemicals	487
	<i>Masatoshi Komiya and Chisato Mori</i>	
20.1	Introduction	487
20.2	Strategy for Establishment of a New Risk-assessment Method for Human Foetal Exposure to Multiple Chemicals	488
20.3	Concentrations of Chemicals in Umbilical Cords of Neonates in Japan	490
20.4	Gene Expression in Umbilical Cords	491
20.5	Toxicogenomic Analysis of Human Umbilical Cords	494
20.5.1	Principal Components Analysis	495
20.5.2	Hierarchical Cluster Analysis	495
20.5.3	Relation between Chemical Concentration and Gene Expression in Umbilical Cords	497
20.5.4	Genes Contributing to Grouping of the Umbilical Cords	499
20.6	Conclusions	502
	References	503

21	Genetic Variability: Implications for Toxicogenomic Research	507
	<i>Gilbert Schönfelder, Dieter Schwarz, Thomas Gerloff, Martin Paul, and Ivar Roots</i>	
21.1	Introduction	507
21.2	Toxicity Due to Genetic Variability of Xenobiotic-metabolizing Enzymes	508
21.2.1	Genetic Variability in Carcinogen Activation by CYP450 Enzymes	509
21.2.2	Toxicity by Variants of Thiopurine Methyltransferase (TPMT)	517
21.2.3	Dihydropyrimidine Dehydrogenase	518
21.2.4	UDP-glucuronosyl Transferase Enzymes	520
21.3	Involvement of Xenobiotic Transporter Systems in Toxicogenomics	521
21.3.1	MDR1 (ABCB1)	522
21.3.2	Multidrug Resistance-related Proteins (MRPs, ABCC)	525
	<i>References</i>	527
22	Profiling of Peripheral Blood Gene Expression to Search for Biomarkers	535
	<i>Arno Kalkuhl and Mario Beilmann</i>	
22.1	Introduction	535
22.2	Objective	536
22.3	Methods	537
22.3.1	Animal Study	537
22.3.2	RNA Isolation	538
22.3.3	Differential Gene Expression Analysis and Statistics	539
22.4	Results and Discussion	540
22.4.1	Comparison of Analyzing Two Different Blood Cell Populations	540
22.4.2	Hemogram/Histopathology in the Animal Study	542
22.4.3	Analysis of the Number of Significantly Deregulated Genes	542
22.4.4	Analysis of Deregulated Genes in Blood after Cyclosporin A Administration	545
22.4.5	Analysis of Genes Deregulated in Blood and Target Organ	551
22.5	Summary	556
	<i>References</i>	556
23	How Things Could Be Done Better Using Toxicogenomics: A Retrospective Analysis	561
	<i>Laura Suter and Rodolfo Gasser</i>	
23.1	Introduction	561
23.2	Case Example: Two 5-HT ₆ Receptor Antagonists Displaying Similar Pharmacological Activity and Different Toxicity Profiles	562
23.2.1	Pharmacological Characteristics of the Compounds	562
23.2.2	Toxicological Findings in Rats and Dogs	563

23.3	The use of Toxicogenomics (Retrospectively) to Evaluate Hepatic Liability	564
23.4	Classification of Compounds with the Use of a Reference Gene Expression Database	566
23.4.1	Differentiation of Two Pharmacologically Closely Related Compounds	567
23.4.2	Use of Gene Expression for Mechanistic Hypothesis Generation	569
23.4.3	Corroboration of the Mechanistic Hypothesis I: Validation of the Technology	573
23.4.4	Corroboration of the Mechanistic Hypothesis II: <i>in vitro</i> Studies	575
23.5	Conclusions and Outlook	578
	References	581
24	Toxicogenomics Applied to Hematotoxicology	583
	<i>Yoko Hirabayashi and Tohru Inoue</i>	
24.1	Introduction: Forward and Reverse Genomics	583
24.2	Hematopoietic Stem/Progenitor Cells in Hematotoxicology	585
24.3	Molecular Signature of Stemness of Hematopoietic Stem/Progenies	588
24.4	Radiation Hematotoxicity and Leukemogenesis	591
24.4.1	Radiation Effects on Hematopoietic Stem/Progenitor Cells	591
24.4.2	Radiation Exposure and Gene Expression Microarray	593
24.5	Benzene-induced Hematotoxicity and Leukemogenesis	594
24.5.1	Benzene Exposure and Cell Cycle in Hematopoietic Stem/Progenitor Cells	594
24.5.2	Gene-expression Profile after Benzene Exposure in WT Mice	596
24.5.3	Cell-cycle-related Genes in p53 KO and WT Mice	598
24.5.4	Apoptosis-related Genes in p53 KO and WT Mice	601
24.5.5	DNA-repair-related Genes in the p53 Gene Network	601
24.6	Summary	602
	References	604

The National Toxicogenomic Program/Initiatives

25	The National Toxicogenomics Program	611
	<i>James K. Selkirk, Michael D. Waters, and Raymond W. Tennant</i>	
25.1	Introduction: The National Center for Toxicogenomics	611
25.2	Risk Assessment	613
25.3	The NCT Strategy	614
25.4	Toxicogenomics Broadly Defined	615
25.5	The Chemical Effects in Biological Systems (CEBS) Knowledge Base	617
25.6	Conclusions	618
	References	619

26	Toxicogenomics: Japanese Initiative	623
	<i>Tetsuro Urushidani and Taku Nagao</i>	
26.1	The Present State of Drug Development Genome Science	623
26.2	The Necessity of Toxicogenomics	625
26.3	Toxicogenomics Project 2002–2007	626
26.3.1	Planning Process and the Present Organization	626
26.3.2	Contents of the Project	627
26.3.3	Advantage and Originality of the Project	629
26.4	Future Perspectives and Conclusions	630
	<i>References</i>	631
 Point of View from Regulatory Authorities and Ethical Aspects		
27	Toxicogenomics in Need of an ICH Guideline? Experiences from the Past	635
	<i>Frauke Meyer and Gerd Bode</i>	
27.1	Introduction	635
27.2	Application Options for Toxicogenomics	636
27.2.1	Comparative/Predictive Toxicogenomics	636
27.2.2	Mechanistic Studies (Mode of Action)	637
27.2.3	Risk Assessment	637
27.2.4	Dose-dependent Toxicity	638
27.2.5	Interspecies Extrapolation	638
27.2.6	Human Biomarkers of Exposure	638
27.2.7	Regulatory Acceptance: Current Status	639
27.3	ICH Process for Harmonization of Guidelines: Experience from the Past	640
27.3.1	Overview	640
27.3.2	ICH Carcinogenicity Guidelines as a Case Study: Experience with the Implementation of Alternative Models in Cancer Risk Assessment	641
27.4	Incorporation of Toxicogenomics into Drug Development, Evaluation, and Regulation: Benefits versus Risks	645
27.4.1	General Criteria for Successful Exploitation	645
27.4.2	Evaluation Process: Current Status	651
27.5	Summary and Outlook	653
	<i>References</i>	655
Subject Index		657